Snapshot

The Abridged review (Type 2) pathway has been developed by the Zambia Medicines Regulatory Authority of Zambia.

This pathway can be used where This pathway is for legacy molecules with minimal risk. An abridged review will therefore be conducted for established products that are considered to be of low risk. .

This pathway accelerates the regulatory review process.

It is an abridged review (a reliance pathway).

351 calendar days.